Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals (2015)

Peer-Reviewed Study · Chul Kim; Vinay Prasad · October 19, 2015

Chul Kim et al., 2015-10-19: Research letter reviewing all FDA cancer approvals 1 Jan 2008 to 31 Dec 2012: 54 approvals, 36 (67%) on a surrogate; after median 4.4 years follow-up only 5 had been shown to improve overall survival, 18 had failed to, and 13 remained unknown.

During our study period, 36 of 54 contemporary cancer drug approvals (67%) were made on the basis of a surrogate end point.

Results (HTML full text)

Chul Kim et al., 2015-10-19: Research letter reviewing all FDA cancer approvals 1 Jan 2008 to 31 Dec 2012: 54 approvals, 36 (67%) on a surrogate; after median 4.4 years follow-up only 5 had been shown to improve overall survival, 18 had failed to, and 13 remained unknown. Funding: none reported. COI: 'Conflict of Interest Disclosures: None reported.' Kim's affiliation is the National Cancer Institute (US federal); Prasad's is Oregon Health and Science University. Comparator: regulatory approvals, not a trial; survival gains assessed against whatever the pivotal trial used (often PFS). The letter also notes bevacizumab's breast-cancer accelerated approval was later removed. Study type: other.